Physician profile

Bufford Moore

Family Medicine · Baytown, TX

NPI 1881697183

$4,528.17

in general payments reported to CMS, 2019-2025

43 companies · $1,052 in 2025

The $1,052 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,909.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $747.10 2023-2025 Airsupra, Farxiga, Breztri
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $641.39 2023-2025 Caplyta
Lilly USA, LLC $445.98 2023-2025 Mounjaro, Zepbound, Jardiance
Astellas Pharma US INC $217.76 2023-2025 Veozah
Glaxosmithkline, LLC. $211.11 2023-2025 Arexvy, Trelegy Ellipta
Smith+Nephew, INC. $175.38 2019-2021
Novo Nordisk INC $158.01 2024-2025 Ozempic, Rybelsus
Bayer Healthcare Pharmaceuticals INC. $150.76 2024-2025
Aimmune Therapeutics, INC. $140.68 2024-2025 Zenpep
Nestle Healthcare Nutrition INC. $140.08 2023
Abbvie INC. $138.01 2023-2025
Pfizer INC. $129.95 2023-2024
Otsuka America Pharmaceutical, INC. $106.58 2023-2024 Rexulti, Nuedexta, Abilify Maintena
Exact Sciences Corporation $93.35 2023-2025 Cologuard Collection Kit
Tela Bio, INC. $89.88 2022-2023 Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex)
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Axogen $80.28 2019
Musculoskeletal Transplant Foundation INC. $65.54 2019-2021
Azurity Pharmaceuticals, INC. $63.70 2024 Horizant
Inspire Medical Systems, INC. $58.05 2024-2025 Inspire
Dexcom, INC. $54.52 2023-2024 Dexcom G6 Transmitter
Novartis Pharmaceuticals Corporation $53.41 2022-2023
Endo Pharmaceuticals INC. $44.96 2021-2022
Tolmar, INC. $44.64 2025 Jatenzo
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $40.49 2025 Xifaxan
Misonix INC $40.48 2019
Acell, INC. $30.58 2020
Neurocrine Biosciences, INC. $30.13 2025
Sumitomo Pharma America, INC. $29.77 2024 Gemtesa
Antares Pharma, INC. $26.96 2025 Xyosted
Axsome Therapeutics, INC. $26.22 2024 Sunosi
Kci USA, INC. $26.09 2020-2021
Kerecis Limited $25.99 2020
Amarin Pharma, INC. $24.76 2023
Lundbeck LLC $23.85 2025 Rexulti
Boehringer Ingelheim Pharmaceuticals, INC. $23.33 2025 Jardiance
Abbott Laboratories $20.22 2025 Freestyle Libre 3
Pacira Pharmaceuticals Incorporated $19.74 2021
Janssen Pharmaceuticals, INC $18.93 2024 Xarelto
Integra Lifesciences Corporation $15.82 2021
Esperion Therapeutics, INC. $15.43 2025 Nexletol
Vanda Pharmaceuticals INC. $14.32 2025 Fanapt
Extremity Medical $12.68 2021
Aroa Biosurgery Incorporated $11.26 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bufford Moore

$4,528.17

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $1,052 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/39503/bufford-moore

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.